Small Devices, Big Problems: Addressing the Global Warming Potential of Metered-Dose Inhalers

Rabin, Alon; Harlan, Emily A; Ambinder, Alexander J.

doi:10.1513/annalsats.202202-131vp

Cited by 11 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(21) A escolha do paciente também pode ser melhorada aumentando-se a difusão de informações disponíveis ao público sobre o impacto ambiental de diferentes produtos inalatórios. (2,14,27,28) Pepper et al (29) alertaram que há evidências de que a exposição em curto prazo ao ozônio pode causar morbidade em indivíduos com asma e sugeriram que exposições a níveis abaixo do padrão atualmente permitido (30) podem estar associadas ao aumento do uso de SABA.…”

Section: Cuidados Médicosunclassified

“…No entanto, os medicamentos que usamos para tratar doenças respiratórias como asma e DPOC, que são doenças agravadas pelas mudanças climáticas, também estão causando mudanças climáticas. (27) Do ponto de vista da indústria e do governo, várias empresas farmacêuticas e organizações nacionais de saúde desenvolveram compromissos 'Net Zero' para atingir zero emissões de carbono em suas operações. (37) Para empresas que atualmente fabricam IPD contendo HFC, esses podem representar uma proporção substancial de toda a pegada de carbono da empresa.…”

Section: Considerações Finaisunclassified

See 1 more Smart Citation

Environmental impact of inhaler devices on respiratory care: a narrative review

Urrutia-Pereira

Chong-Neto

Winders³

et al. 2022

J Bras Pneumol.

View full text Add to dashboard Cite

Climate change is a huge and present threat to human health. This article aims to deepen the knowledge about the environmental impact of inhaler devices on their carbon footprint for patients and health professionals, providing information that allows a better choice of the type of device to be prescribed for the treatment of asthma and COPD. This narrative and nonsystematic review was carried out by searching databases (PubMed, Google Scholar, SciELO, and EMBASE) for articles published between 2017 and 2022, written in Portuguese or in English, using the search words "inhalation device" OR "environmental." The review showed that global warming cannot be addressed by focusing only on inhaler devices. However, the devices that we use to treat respiratory diseases such as asthma and COPD, which are diseases that are aggravated by climate change, are also causing that change. Therefore, health professionals, patient organizations, and industries should take a lead in health policies to offer affordable alternatives to inhalers containing hydrofluoroalkane.

show abstract

Section: Cuidados Médicosunclassified

Section: Considerações Finaisunclassified

Environmental impact of inhaler devices on respiratory care: a narrative review

Urrutia-Pereira

Chong-Neto

Winders³

et al. 2022

J Bras Pneumol.

View full text Add to dashboard Cite

show abstract

“…The United Kingdom has adopted a strategy of encouraging use of dry-powder inhalers for precisely this reason, and some commentators have called for the same approach in the United States. 5 Such a multipronged approach could help avert a repeat of the unnecessary and harmful financial excesses that followed the ban on CFC inhalers. Albuterol is one of many drug-device combinations now on the U.S. market; limiting costly product hops on complex therapies should be a…”

mentioning

confidence: 99%

Product Hopping in the Drug Industry — Lessons from Albuterol

Wouters

Feldman

2022

N Engl J Med

View full text Add to dashboard Cite

Many patients with asthma or chronic obstructive pulmonary disease (COPD) rely on albuterol, a short-acting 2 agonist, to relieve acute symptoms of bronchospasm. The Food and Drug Administration (FDA) approved the first two albuterol inhalers -Glaxo Wellcome's Ventolin and Schering's Proventil -in 1981. Each went off patent in 1989, and by 1997 there were four generic albuterol inhalers on the U.

show abstract

“…We read with interest the perspective by Dr. Rabin and colleagues on “opportunities to transform the inhaler market to address an important source of GHG (greenhouse gas) emissions” ( 1 ). Their conclusions include that the use of metered dose inhalers (MDIs) containing hydrofluoroalkanes (HFA) should be minimized because of the carbon footprint, and prescribing should be systemically directed away from these products, and “would represent a major symbolic victory”.…”

mentioning

confidence: 99%